Sanofi's 2026 Outlook: A 'Catalyst-Light' Year Ahead as Citi Initiates Coverage with Neutral Stance
Citi Research has initiated coverage on Sanofi with a Neutral rating and an €85 price target, citing pipeline setbacks and a lack of near-term catalysts. The analysis comes as the French pharma giant reports positive Phase 3 results for its eczema drug amlitelimab.